ViaLase’s Non-Incisional Glaucoma Treatment Showcases Promising Efficacy and Safety in Pivotal Trial

ViaLase provides update on its nonincisional technology for treating glaucoma.

In a recent interview, Rick Lewis, the chief medical officer for ViaLase, discussed the company’s promising nonincisional glaucoma treatment. ViaLase is a surgical startup that aims to treat glaucoma by creating a 500-micron-wide channel in the trabecular meshwork using a nonincisional technique. The company utilizes imaging techniques such as gonioscopic images and OCT to visualize the trabecular meshwork and accurately place a channel almost anywhere in the meshwork for 360 degrees.

ViaLase has recently completed a safety study that demonstrated the effectiveness and safety of their treatment. The study involved monitoring patients for up to 3 years and showed that the intraocular pressure dropped into the low teens without any adverse events. Patients experienced good outcomes, highlighting the durability of the procedure with a single channel of 500 by 200 microns being sufficient to control pressure.

The company has now moved forward with a pivotal trial that has enrolled all patients and randomized them between femtolaser treatment and SLT. With a total of 152 patients (76 in each group), the trial focuses on determining both efficacy and safety. Data collection is ongoing, with a 6-month follow-up expected next month. Based on the positive results indicating good safety and efficacy of their nonincisional approach to treating glaucoma, ViaLase plans to lock the database and file for FDA approval later this year.

Leave a Reply